Diabetic Nephropathy - A Pipeline Analysis Report

This pipeline analysis report provides detailed insights into the clinical trials landscape of the drug development for diabetic nephropathy including molecules at pre-clinical and discovery stage. The report also offers comprehensive information about the therapeutic assessment of the pipeline molecules based on various segmentations such as therapy, route of administration, and target.

Overview of the drug development pipeline for diabetic nephropathy

Diabetic nephropathy is a kidney-related complication of type I diabetes and type II diabetes. It is also called diabetic kidney disease. Generally, 4-10 people with diabetes gradually develop kidney diseases. Diabetic nephropathy limits the ability of the kidney cells and damages the blood vessels, affecting the organ’s ability to filter out waste. Thus, the waste builds up in the blood instead of being excreted. The best way to prevent or delay diabetic nephropathy is maintaining a healthy lifestyle and treating diabetes and high blood pressure at the right time. With time, the disease damages the delicate filtering system of the kidneys. Early treatment may prevent the disease or slow down its progression, thereby reducing the chance of complications. Diabetic nephropathy may also lead to kidney failure, which is also called as end-stage kidney disease. Kidney failure is a life-threatening condition, and at this stage, the only treatment options are dialysis or kidney transplant. The most effective approach for the treatment of diabetic nephropathy is emerging to be monotherapy.

According to this pipeline analysis report, all the drug molecules in the pipeline are being developed for diabetic nephropathy. Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.

Companies covered

This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of diabetic nephropathy. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug molecules discontinued by companies.

Some of the companies covered in this pipeline analysis report are –

• Bayer
• Bird Rock Bio
• BLR Bio

Therapeutic assessment of the drug development pipeline for diabetic nephropathy by route of administration

• Oral
• Intravenous
• Subcutaneous
• Intramuscular
• Unknown

The oral route of administration (ROA) involves the delivery of the drug directly into the mouth cavity and in the intravenous technique, the drug molecules are injected into the veins as a liquid substance, which will have a more direct effect on the target cells.

Therapeutic assessment of the drug development pipeline for diabetic nephropathy by therapy

• Monotherapy
• Unknown

According to this pipeline analysis report, most of the molecules that are currently in the drug pipeline for diabetic nephropathy are being developed as monotherapy drugs and most of these molecules are in the pre-clinical stage of development.

Key questions answered in the report include

• What are the gene therapy molecules in the various development stages for diabetic nephropathy?
• What are the companies that are currently involved in the development of drug molecules for diabetic nephropathy?
• Insight into discontinued/inactive molecules with appropriate reasoning?
• What are the major regulatory authorities approving drugs in various regions?
• Detailed profiling of each active molecule

Technavio also offers customization on reports based on specific client requirement.